Archive
540 articles, sorted by publication time.
This is not another cell therapy simply pursuing stronger immune attack; TREGZI stratifies, quantifies, and reinfuses donor cells, seeking to give allogeneic transplantation greater ability to control long-term immune costs, beyond clearing cancer.
The FDA has approved a subcutaneous CD38 antibody for high-risk smoldering multiple myeloma, allowing some patients to receive intervention before organ damage occurs; but it also pushes the medical judgment of “when to start treatment” toward more refined risk stratification.
Sandra Demaria’s appearance at the SITC Biotech Strategic Meeting added a layer of realism to the celebratory tone of Cancer Immunotherapy Month: moving from clinical miracles to a medical system that is predictable, affordable, and able to reach more patients remains the field’s most difficult project.
DelveInsight says at least five major pharmaceutical companies are investing in HPV-positive oropharyngeal cancer R&D, showing that this field, formed at the intersection of viruses, immunity, and head and neck cancer, is expanding; however, publicly available information remains limited, and a “robust” pipeline does not mean patients are already close to new therapies.
Drug-resistant gonorrhea is approaching the limits of existing antibiotics; a new study brings AI screening into an experimental platform closer to human tissue, putting the candidate molecule MP20 not only through computer prediction but also through an infection-model test in a "vagina chip."
The FDA has moved the eligible age for a CRISPR cell therapy sharply earlier, potentially allowing children with severe disease to avoid repeated pain, transfusions, and organ damage sooner; but the complex treatment process, long-term follow-up, and access issues also become more urgent as the age range expands.
The significance of the FDA’s clearance is not just that it adds another tool for post-transplant care in blood cancer; it pushes the treatment focus toward a more nuanced question: how to let a new immune system develop strength without turning against the patient.
The deal moves AI drug development from algorithm demonstrations toward asset licensing, but until the target, clinical stage, and validation data are disclosed, its real value will still have to be answered by experiments and the regulatory path.
The FDA has approved Orca Bio’s TREGZI for some adult patients with hematologic malignancies, moving allogeneic hematopoietic stem cell transplantation into a more refined design of cellular composition; it brings clinical signals of reduced chronic graft-versus-host disease, while also putting manufacturing, accessibility, and long-term safety on the same test paper.
Anthropic’s newly launched research workbench is no longer selling only chat capabilities. Instead, it is trying to put database queries, molecular visualization, and genome browsing into a single research environment; its real test will be whether it can leave a sufficiently clear chain of evidence for biomedical judgments.
The FDA approval of Orca Bio's donor cell therapy TREGZI is not about pushing the immune system harder, but about trying to restore order after hematopoietic stem cell transplantation; this shifts prevention of chronic graft-versus-host disease from drug-based suppression toward precise regulation of cellular composition.
The decision extends the role of immune cell therapy from attacking cancer cells to regulating runaway immune responses after transplantation; but with limited public data, its clinical value still needs to be weighed in the context of patient characteristics, treatment accessibility, and long-term safety.